BLACK DIAMOND THERAPEUTICS, INC. Operating Lease Cost
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Operating Lease Cost of $778.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $778.00K, a 26.19% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $785.00K, a 25.52% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $967.00K, a 8.34% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $1.05M, a 0.00% change year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $4.13M, a 2.09% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $4.22M, a 0.00% change from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $4.22M, a 0.26% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $4.23M, a 39.45% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $778.00K 10-Q · filed 2026-08-05 | $1.56M 10-Q · filed 2026-08-05 | $2.53M derived: sum of 3 quarters · filed 2026-08-05 | $3.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $785.00K 10-Q · filed 2026-05-07 | $1.75M derived: sum of 2 quarters · filed 2026-05-07 | $2.81M derived: sum of 3 quarters · filed 2026-05-07 | $3.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $967.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.02M derived: sum of 2 quarters · filed 2026-03-16 | $3.08M derived: sum of 3 quarters · filed 2026-08-05 | $4.13M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-06 | $2.11M derived: sum of 2 quarters · filed 2026-08-05 | $3.16M 10-Q · filed 2025-11-06 | $4.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.05M 10-Q · filed 2026-08-05 | $2.11M 10-Q · filed 2026-08-05 | $3.16M derived: sum of 3 quarters · filed 2026-08-05 | $4.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.05M 10-Q · filed 2026-05-07 | $2.11M derived: sum of 2 quarters · filed 2026-05-07 | $3.16M derived: sum of 3 quarters · filed 2026-05-07 | $4.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.11M derived: sum of 2 quarters · filed 2026-03-16 | $3.16M derived: sum of 3 quarters · filed 2026-03-16 | $4.22M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.05M 10-Q · filed 2025-11-06 | $2.11M derived: sum of 2 quarters · filed 2025-11-06 | $3.16M 10-Q · filed 2025-11-06 | $4.22M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.05M 10-Q · filed 2025-08-07 | $2.11M 10-Q · filed 2025-08-07 | $3.16M derived: sum of 3 quarters · filed 2025-08-07 | $4.22M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.05M 10-Q · filed 2025-05-12 | $2.11M derived: sum of 2 quarters · filed 2025-05-12 | $3.16M derived: sum of 3 quarters · filed 2025-05-12 | $4.22M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.11M derived: sum of 2 quarters · filed 2025-03-06 | $3.16M derived: sum of 3 quarters · filed 2025-03-06 | $4.22M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.05M 10-Q · filed 2024-11-05 | $2.11M derived: sum of 2 quarters · filed 2024-11-05 | $3.16M 10-Q · filed 2024-11-05 | $4.22M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $1.05M 10-Q · filed 2024-08-06 | $2.11M 10-Q · filed 2024-08-06 | $3.16M derived: sum of 3 quarters · filed 2024-08-06 | $4.22M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.05M 10-Q · filed 2024-05-09 | $2.11M derived: sum of 2 quarters · filed 2024-05-09 | $3.17M derived: sum of 3 quarters · filed 2024-05-09 | $4.22M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.11M derived: sum of 2 quarters · filed 2024-03-12 | $3.17M derived: sum of 3 quarters · filed 2024-03-12 | $4.23M 10-K · filed 2024-03-12 |
| 2022-09-30 | $1.06M 10-Q · filed 2023-11-06 | $2.11M derived: sum of 2 quarters · filed 2023-11-06 | $3.17M 10-Q · filed 2023-11-06 | $4.23M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $1.06M 10-Q · filed 2023-08-11 | $2.12M 10-Q · filed 2023-08-11 | $3.17M derived: sum of 3 quarters · filed 2023-08-11 | $4.07M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-09 | $2.12M derived: sum of 2 quarters · filed 2023-05-09 | $3.02M derived: sum of 3 quarters · filed 2023-05-09 | $3.63M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.96M derived: sum of 2 quarters · filed 2023-03-09 | $2.57M derived: sum of 3 quarters · filed 2023-03-09 | $3.03M 10-K · filed 2023-03-09 |
| 2021-09-30 | $900.00K 10-Q · filed 2022-11-08 | $1.51M derived: sum of 2 quarters · filed 2022-11-08 | $1.98M 10-Q · filed 2022-11-08 | $2.36M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $613.00K 10-Q · filed 2022-08-09 | $1.07M 10-Q · filed 2022-08-09 | $1.46M derived: sum of 3 quarters · filed 2022-08-09 | $1.73M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $462.00K 10-Q · filed 2022-05-11 | $843.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.12M derived: sum of 3 quarters · filed 2022-05-11 | $1.17M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $655.00K derived: sum of 2 quarters · filed 2022-03-17 | $711.00K derived: sum of 3 quarters · filed 2022-03-17 | $767.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $274.00K 10-Q · filed 2020-11-10 | $330.00K derived: sum of 2 quarters · filed 2020-11-10 | $386.00K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $56.00K 10-Q · filed 2020-08-11 | $112.00K 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $56.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |